Carsten Reissner

Title: Carsten Reissner: Innovator in Bone Morphogenetic Protein Variants

Introduction

Carsten Reissner is a notable inventor based in Muenster, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of bone morphogenetic protein variants. His work focuses on enhancing the efficacy of these proteins, which play a crucial role in bone formation and repair.

Latest Patents

Reissner holds a patent for "Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity." This invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1. The patent is characterized by at least two amino acid substitutions, with a first substitution occurring at specific positions of the amino acid sequence. This innovation has potential applications in medical treatments related to bone health.

Career Highlights

Carsten Reissner is associated with Haase Investments UG, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on regenerative medicine and orthopedic applications. With a focus on innovative solutions, Reissner is dedicated to improving patient outcomes through his inventions.

Collaborations

Reissner collaborates with esteemed colleagues such as Georg N. Duda and Julia Zimmer. Their combined expertise enhances the research and development process, fostering an environment of innovation and discovery.

Conclusion

Carsten Reissner is a prominent figure in the field of biotechnology, with a focus on bone morphogenetic proteins. His patent for BMP2 variants showcases his commitment to advancing medical science. Through his work, he contributes to the ongoing evolution of treatments for bone-related conditions.